February 11-12, 2013 The Waldorf Astoria New York
15th Annu al Event Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.
5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event.
7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
-2- Advisory Committee
Tom Brakel, MD Portfolio Manager, Federated Kaufmann Funds John Chambers Managing Director & Head of Healthcare Investment Banking, Roth Capital Partners
Michael Gilman, PhD Senior Vice President Early-Stage Programs, Biogen Idec Michael Hay Vice President, BioMedTracker Product Manager, Sagient Research Systems
Peter Kolchinksky, PhD Managing Partner, RA Capital Management, LLC
Arlene Morris CEO, Syndax Pharmaceuticals
Oleg Nodelman Founder & Managing Director, EcoR1 Capital
David Sable, MD Portfolio Manager, Special Situations Fund
Joel Sendek Managing Director, Head Healthcare Equity Research, Stifel Nicolaus
Nathan Tinker, PhD Executive Director New York Biotechnology Association
-3- Fireside Chats
Fireside chats feature candid discussions between biopharma executives and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.
Jean-Jacques Bienaimé Chief Executive Officer BioMarin Pharmaceutical Inc.
N. Anthony Coles Chairman & CEO Onyx Pharmaceuticals, Inc.
Robert Hugin Chairman and Chief Executive Officer Celgene Corporation
John C. Lechleiter, PhD Chairman, President and CEO Eli Lilly and Company
John F. Milligan, PhD President and Chief Operating Officer, Gilead Sciences, Inc.
-4- Plenary Sessions
Word on the Street: The Buy-Side View for 2013 Monday, February 11th, 12:00pm – 12:55pm Portfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and ISI Group. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today. Moderator: • Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group Panelists: • Samuel D. Isaly, Managing Partner, OrbiMed Advisors • Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • Nathan Sadeghi-Nejad, Partner, Palkon Capital Management Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff Tuesday, February 12th, 4:00pm – 4:55pm The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces. Although the fiscal cliff has been averted for now, an unsteady economy and concerns over U.S. debt remain. This session will feature two former White House Chiefs of Staff who have served in the trenches under President Bill Clinton and President George W. Bush. BIO’s CEO and former Congressman, James C. Greenwood, will lead an in depth and lively discussion between Joshua Bolten and John Podesta, who will proffer their views of the political landscape, the outlook for the next four years, the outcome of these key issues and more. Moderator: • James C. Greenwood, President & CEO, BIO Panelists: • Joshua Bolten, 22nd White House Chief of Staff • John Podesta, Former White House Chief of Staff and Founder and Chair, Center for American Progress
Mark Schoenebaum Samuel D. Isaly Oleg Nodelman Nathan James C. Greenwood Joshua Bolten John Podesta Sadeghi-Nejad
-5- Therapeutic Workshops
Oncology: Panning for Gold—Prospecting the Pancreatic Pipeline Monday, February 11th, 10:30am - 11:25am Though pancreatic cancer is the 4th leading cancer malignancy, resulting in nearly 37,000 deaths a year in the US, the pipeline has garnered less attention from industry and the investment community than other oncology indications. There are only two currently approved single agent therapies for this serious disease, but combination treatment regimens are showing tremendous promise yielding a significant increase in overall survival rates. With several phase II and III trials now in the works and positive readouts expected in 2013, the industry is becoming much more intrigued by this potentially underserved space. Hear clinical experts entrenched in the pancreatic cancer late stage treatment pipeline proffer their insights on the future of the disease. Moderator: • Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel, Nicolaus & Company Panelists: • John Chabot, MD, FACS, Chief, Division of GI/Endocrine Surgery and Executive Director, Pancreas Center, New York Presbyterian Hospital/Columbia University • Stewart M. Kroll, Senior Vice President, Clinical Operations and Biostatistics, Threshold Pharmaceuticals • Peter Laivins, Vice President, Late Stage Drug Development, Merrimack Pharmaceuticals • Mark Miocevich, Global Marketing Lead for Abraxane, Celgene • Kenneth H. Yu, MD, Assistant Professor, Memorial Sloan-Kettering Cancer Center
-6- Orphan Drugs: Making Rare Diseases Rarer Tuesday, February 12th, 9:00am - 9:55am The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field. Moderator: • Ritu S. Baral, Principal, Sr. Analyst- Biotechnology Equity Research, Genuity Partners Panelists: • Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals • John F. Crowley, Chairman & CEO, Amicus Therapeutics • Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa • Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit Oncology: The CLL Chronicles—The Next Chapter in Clinical Developments Tuesday, February 12th, 12:00pm - 12:55pm Moderator: • Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company Panelists: • Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of Medicine CLL Research and Treatment Program • John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center • Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
-7- Business Roundtables
Show Me the Money: Reimbursement in an ACA World Monday, February 11, 9:00am - 9:55am With many key provisions of the Affordable Care Act (ACA) slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Additionally, nearly 30 million more Americans will now have access to health insurance. How will this new environment affect relationships between patients, payors, providers and biopharma companies? How could changes to federal health plans and the creation of state-run insurance exchanges alter biopharma company strategy, from business development to R&D activities? This reimbursement roundtable will feature payors, providers, and other stake- holders from across the industry discussing ACA implementation and the wider reimbursement landscape. Moderator: • Roger Longman, Chief Executive Officer, Real Endpoints Panelists: • Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center • Rena Conti, PhD, Assistant Professor of Health Policy & Economics, University of Chicago • Ed Pezalla, MD, MPH, National Medical Director for Pharmacy Policy and Strategy, Office of the Chief Medical Officer, Aetna • Cynthia Smith, Vice President, Market Access & Commercial Development, Affymax The Road Less Traveled: Alternative Avenues to Public Markets Tuesday, February 12th, 1:30pm - 2:25pm While an IPO has long been a preferred way to go public, an increasing number of companies have employed alternate routes to the public markets, using reverse mergers, Form-10 self-filings, and variations of each to avoid the expense, uncertainty, and complexity of the IPO process. In particular, these alternate avenues may offer advantages by separating the straightforward process of becoming a publicly-filing company from less predictable fund raising. Hear an experienced attorney, executives, and crossover investors who have traveled these new paths discuss lessons learned, deal structures, and how recent legislation like the JOBS Act could affect public exits. Moderator • William Hicks, Member, Mintz Levin Panelists: • Charles Crain, Manager, Policy & Research, BIO • Michelle Dipp, MD, PhD, Chief Executive Officer & Co-Founder, OvaScience • Daniel B. Dubin, MD, Vice Chairman, Founder of MEDACorp, Leerink Swann • Peter Kolchinsky, PhD, Managing Partner, RA Capital
-8- Putting a Ring on It—When Drug Development Partnerships Become Acquisitions Tuesday, February 12th, 12:00pm-12:55pm Many recent biopharma acquisitions have started as drug development collaborations including GlaxoSmithKline’s takeover of Human Genome Sciences and Amgen’s purchase of Micromet. How do traditional drug development relationships grow into all-out acquisitions? What business or clinical considerations can prompt the larger company to “take the plunge” and acquire their smaller partner? What deal-breakers should both parties watch for? The panel will feature seasoned business development executives discussing the do’s and don’t’s of taking biopharma collaborations to the next level. Moderator: • Jeff Stewart, Senior Engagement Manager, Campbell Alliance Panelists: • Michael Gilman, PhD, Senior Vice President, Early Stage Programs, Biogen Idec • Michael Margolis, RPh, Managing Director, ROTH Capital Partners • Effie Toshav, Partner, Corporate, Fenwick & West LLP Small Companies Thinking Big—China Tactical Strategies Monday, February 11th, 3:30pm - 4:25pm Big pharmaceutical companies aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With more limited resources than multinational biopharma companies, how can these smaller companies operate efficiently and give Chinese patients access to their innovative products? What deal making strategies have proven successful? Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China. Moderator: • Jimmy Zhang, PhD, MBA, Managing Director, MSD Early Investments – Greater China, Merck & Co., Inc. Panelists: • Friedhelm Blobel, PhD, President, CEO, & Director, SciClone Pharmaceuticals • Alan Eisenberg, Executive Vice President, Business Development and Emerging Companies Section, BIO • Kewen Jin, Managing Director, Nimbus Innoworks • Laurence Reid, PhD, Senior Vice President, Chief Business Officer, Alnylam Pharmaceuticals
-9- Presenting Companies
The 2013 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, for the first time this meeting will also include a unique track that features up to 25 high-caliber and established private company presentations. Presenting Companies* Public Companies Furiex Pharmaceuticals Oxygen Biotherapeutics PRIVATE Companies Aastrom Biosciences Galena BioPharma Palatin Technologies Actinium Pharmaceuticals ACADIA Pharmaceuticals GENFIT PDL BioPharma ALS Therapy Development Advanced Cell Technology GeoVax Labs Pozen Institute Adocia GTx Prima Biomed Aratana Therapeutics ADVENTRX Pharmaceuticals Horizon Pharma ProMetic Life Sciences Catabasis Pharmaceuticals Aegerion iCo Therapeutics Protalix BioTherapeutics CoLucid Pharmaceuticals Affymax Idenix Pharmaceuticals Provectus Pharmaceuticals Fate Therapeutics Agenus Idera Pharmaceuticals pSiVida Corp. Five Prime Therapeutics Alkermes plc ImmunoCellular Therapeutics Q Therapeutics FORMA Therapeutics Alnylam Pharmaceuticals ImmunoGen Regulus Therapeutics GlobeImmune Anteo Diagnostics Immunovaccine ReNeuron Good Start Genetics Anthera Pharmaceuticals Innovus Pharma Repros Therapeutics Hydra Biosciences Antisense Therapeutics Inovio Pharmaceuticals Resverlogix Corp. Immune Design Corp. Apricus Biosciences Intercept Pharmaceuticals Retrophin KaloBios Pharmaceuticals Aradigm Corp. Keryx Biopharmaceuticals Rigel Pharmaceuticals KineMed Arena Pharmaceuticals Lexicon Pharmaceuticals RXi Pharmaceuticals Kinex Pharmaceuticals Astex Pharmaceuticals MDxHealth SciClone Pharmaceuticals Leukemia & Lymphoma Athersys NanoViricides Soligenix Society Atossa Genetics Navidea Stallergenes Melanoma Research Alliance Biodel NeoStem StemCells Mersana Therapeutics BioDelivery Sciences Neuralstem Sucampo Pharmaceuticals International Newron Pharmaceuticals Synergy Pharmaceuticals Mirna Therapeutics BioLineRx Ltd. S.p.A. Synthetic Biologics Onconova Therapeutics Biotie Therapies NicOx S.A. Targacept Polynoma Catalyst Pharmaceutical NovaBay Pharmaceuticals Tekmira Pharmaceuticals Corp. Promedior Partners Novavax Tengion Prosensa Therapeutics CEL-SCI Corporation Novelos Therapeutics TG Therapeutics Proteon Therapeutics Cempra NPS Pharmaceuticals TiGenix N.V. Regado Biosciences ChemoCentryx Nymox Pharmaceutical Tonix Pharmaceuticals Sutro Biopharma Cleveland BioLabs Corporation Transcept Pharmaceuticals Syndax Pharmaceuticals Cyclacel Pharmaceuticals Oculus Innovative Sciences Transition Therapeutics The Michael J. Fox Foundation Cytokinetics Ohr Pharmaceutical Tranzyme Tobira Therapeutics Cytomedix OncoGenex Pharmaceuticals TVAX Biomedical Trevena CytRx Corporation Oncolytics Biotech Venaxis uniQure DARA BioSciences OncoSec Medical Verastem Zafgen DiaMedica Opexa Therapeutics VirtualScopics DURECT Corporation Oragenics Zalicus * As of 01/23/2013 EpiCept Corporation Orexigen Zealand Pharma A\S Eternity Healthcare OvaScience ZIOPHARM Oncology Exelixis OXiGENE Sign up now to present. Email Sondra Behan at [email protected] or call (866) 356-5155 for more information.
-10- Participating Investors
Participating Investors*
ACAP International, Inc. Edison Investment Research Maryland Department of Serrado Capital Acers BioMedical Emerald Advisers Business and Economic Sherbrook Capital Actin Biomed Emergent Rx LLC Development Management, LLC Aegis Capital Corp. Eminent Venture Capital Maz Capital Advisors Sigma Capital Management Aisling Capital Corporation Medical Strategy SimRx Akana Capital Essex Investment Management Medimmune Ventures, Inc. Sio Capital Management American Capital Company, LLC Medpro Investors LLC Skyline Ventures American Portfolios F.Hoffmann-La Roche Ltd Mehta Partners LLC Small Business Technology Apis Capital Favus Institutional Research LLC Merck & Co., Inc Investment Fund Apposite Capital Federated Kaufmann Fund Mercury Fund Sofinnova Ventures Arthritis Foundation Fidelity Investments Millennium Management LLC Sophrosyne Capital Ascendiant Capital Markets LLC FireRock Capital Millennium Partners Green Arrow Special Situations Fund Aspire Capital Fountain Healthcare Partners MLV & Co Spencer Edwards Investment Inc. ATEL Ventures Gagnon Securities Morgan Stanley Spencer Trask Athyrium Capital Gem Partners Morgens Waterfall Vintiadis Stanphyl Capital Atika Capital George Weiss Associates MP Healthcare Venture Stifel Nicolaus Management Atlantic Capital Group Global Corporate Finance ste. Strategy Signal, LLC MSMB Capital Management Atlantis Investment Global Energy Capital LLC Summer Street Research Partners Muse Capital Atlas Venture Golden Seeds LLC SunTrust Robinson Humphrey MVP Capital Partner Auriga Capital Management Goldman Sachs Surveyor Capital Needham & Co. Avior Capital Green Arrow Suvretta Capital New Leaf Venture Partners Bank of America Merrill Lynch Greenwich LifeSciences Symmetry Capital Nextech Invest Ltd. Barclays Griffin Securities Symphony Capital LLC Nordcon Capital Bawcap GRT Capital Syzygy Therapeutics Nowak Ventures, LLC Baxter Healthcare Corporation H.I.G. BioVentures Tech Coast Angels Oppenheimer & Co. BC Capital HBM Partners AG Technological & Investment Opus Point Partners Horizons BDC Venture Capital Hermes Fund Managers Oracle Partners Terrapin Opportunity Fund Bearing Circle Capital, LP HMC OrbiMed Advisors The Astrologers Fund, Inc. BioRevolution Capital, LLC Horizon Technology Finnace Oxford Finance LLC The Channel Group BioYields Hutchin Hill Capital Pacific Rim Ventures The Invus Group Black Diamond Iliad Ventures, LLC Padus Healthcare The Jordan Family Office BlackRock Ingalls & Snyder Paisley and Habermas, Inc The Keiser Foundation Bloom Burton & Co. Innotrove LLC Palkon Capital Management The Livingston Group Boodell & Company ISI Group LLC Pappas Ventures The R. H. Barsom Company Inc Brean Capital, LLC Issaquena Trust Paragon Capital Advisors Third Point Brinson Patrick Securities JAIVC Perceptive Advisors Thomas, McNerney & Partners Burrage Capital Jefferies & Company Pinnacle Associates Three Arch Partners Burrill Securities Jina Ventures Inc. Piper Jaffray & Co Trellus Management BVF Partners LP JMP Securities PK Healthcare Partners TriCygnet LLC Cantor Fitzgerald Kaminski Partners POSCO BioVentures Fund Tryphon Capital Capital Royalty LP Katz Associates Profit Investments UBS Carr Securities Kearny Venture Partners PW Partners U.S. Steel Pension Fund Cato BioVentures Kingsbridge Questrion Research Valence Life Sciences Celtic Therapeutics Knoll Capital Management Management LP Knott Partners, LP Quogue Capital LLC Van Leeuwenhoeck Institute CentreStone Ventures Ladenburg Thalmann QVT Financial VenBio Charlestown Capital Advisors LLC Laidlaw & Company RBC Capital Markets Venrock China Focus Limited Landmark Angels, Inc. Revach Fund Ventures West Capital China Private Equity Group Lazard Asset Management Robert W. Baird Veziris Ventures Citigroup Ledgemont Capital Group Roberts Mitani Viscogliosi Brothers, LLC Columbia University Leviathan Biopharma Group ROTH Capital Partners Visium Asset Management Crede Capital Group, LLC LifeScience Equity Partners, LLC Roundbox Partners WBB Securities LLC Critical Mass Partners LifeTech Capital Roy Healthcare Research WK MAHON & CO. Cross Current Research LLC Lincoln Park Capital RRCM World Tech Ventures, LLC DABAR Investment Associates Little Gem Life Sciences Fund RTW Investments WP Stewart Dawson James Securities Loeb Partners S&P Capital IQ Yorkville Advisors, LLC Easton Capital LSWorks SAC Capital Young Capital Partners EcoR1 Capital Mansa Capital Samtheo Biopharma LLC Edgewood Management LLC Maryland Biotechnology Center SendMed Capital *As of 01/25/2013
-11- One-on-One Meetings
BIO One-on-One Partnering is proprietary software developed by BIO that allows selected registrants to utilize an online database tool to: • Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and senior management in biotech and pharma • Search company and investor profiles
One-on-One Partnering Statistics
Over 1,300 scheduled meetings in 2012 1500 60% growth in scheduled meetings 1200 since 2009 900
600 s Scheduled Meetin Total 300
Company & Investor 88% 0 2009 2010 2011 2012
Company & Company Investor & Investor 9% 3%
-12- Therapeutic Focus
Vaccines: 4% Ophthalmology Diagnostics 4% 3% Rare/Genetic Gastrointestinal Diseases: 3% Disorders: 4% Cardiovascular 4% Oncology Platform/ 27% Discovery: 4% Cell Therapy/ Regenerative Medicine: 5% CNS 16% Metabolic 5% Other 10% Autoimmune/ Inflammation 5% Infectious Diseases: 7%
300+ companies Nearly 600 investors
Market Cap >$1B: 6%
500M-1B 7% <50M 27% 250-500M 11%
100-250M 50-100M 19% 29%
-13- Agenda*
Monday, Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor February 11, 2013 4th Floor 3rd Floor 7:00 – 7:55am Networking Breakfast: Grand Ballroom 8:00 – 8:45am Fireside Chat with Robert Hugin, Chairman and CEO, Celgene Corporation (Astor) Proteon Therapeutics 9:00 – 9:25am Galena Oxygen GTx TBD Show Me BioPharma Biotherapeutics Tobira Therapeutics the Money: Reimbursement Regado Biosciences in an ACA World 9:30 – 9:55am Verastem Transition Oncolytics ChemoCentryx Therapeutics ALS TDI (PAG) Biotech (Jade) CoLucid Advanced Cell Pharmaceuticals ImmunoCellular Rigel 10:00 – 10:25am Technology DiaMedica Therapeutics Pharmaceuticals Actinium Pharmaceuticals Onconova Therapeutics 10:30 – 10:55am ReNeuron GENFIT Furiex NPS Oncology: uniQure Pharmaceuticals Pharmaceuticals Panning for Gold—Prospecting Fate Therapeutics 11:00 – 11:25am Palatin CEL-SCI Corporation Repros Lexicon the Pancreatic Technologies Zafgen Therapeutics Pharmaceuticals Pipeline (Jade) LL Society (PAG) NovaBay Provectus TONIX 11:30 – 11:55am Pharmaceuticals Pharmaceuticals Five Prime Pharmaceuticals TBD Therapeutics 12:00 – 12:55pm Openingg Plenary Session: Word on the Street – Buy-Side View for 2013 (Jade) – Box Lunch
Catabasis Fireside Chat Pharmaceuticals with John Anteo Lechleiter, PhD, 1:00 – 1:25pm Diagnostics Atossa Genetics Targacept TBD Chairman, Promedior President and CEO, Eli Lilly (Astor, 1:00-1:45pm) KineMed 1:30 – 1:55pm ProMetic Life CytRx Corporation Biotie Therapies Synergy Sciences Rib-X Pharmaceuticals Pharmaceuticals
Good Start Genetics Cleveland Zealand 2:00 – 2:25pm NeoStem Novelos Therapeutics BioLabs Pharma A/S Biosimilars: Beyond the New Opexa Cyclacel Keryx Pathway for 2:30 – 2:55pm VirtualScopics TBD Biopharma- Approval (Jade) Therapeutics Pharmaceuticals ceuticals Oculus Innovative Idera Biodel MDxHealth Novavax 3:00 – 3:25pm Pharmaceuticals Sciences Antisense 3:30 – 3:55pm Q Therapeutics Eternity Healthcare TG Therapeutics Navidea Small Companies Therapeutics Thinking Big: China Tactical Catalyst Anthera 4:00 – 4:25pm Pharmaceutical RXi Pharmaceuticals Venaxis Stallergenes Strategies Partners Pharmaceuticals (Jade)
Tranzyme Horizon Intercept 4:30 – 4:55pm Cytomedix Ohr Pharmaceutical Pharma Pharmaceuticals 5:00 – 6:30pm BIO CEO Reception (Empire Room)
* As of 1/23. Program schedule subject to change. Please go to www.bio.org/bioceo or visit us onsite for updates.
-14- Tuesday, Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor February 12, 2013 4th Floor 3rd Floor 7:00 – 7:40am Networking Breakfast (Grand Ballroom) 7:45 – 8:25am Fireside Chat with N. Anthony Coles, MD, Chairman & CEO, Onyx Pharmaceuticals (Astor) Polynoma 8:30 – 8:55am TiGenix N.V. StemCells OvaScience Exelixis Trevena Sutro Biopharma 9:00 – 9:25am Athersys Zalicus Resverlogix ImmunoGen Syndax Corp. Orphan Drugs: Pharmaceuticals Making Rare GlobeImmune Diseases Rarer Inovio (Jade) 9:30 – 9:55am Pharmaceuticals Neuralstem Aratana Cempra Affymax Therapeutics Immune Design Corp. 10:00 – 10:25am Apricus ADVENTRX Agenus ACADIA Biosciences Pharmaceuticals FORMA Pharmaceuticals Therapeutics Mersana Tekmira Therapeutics Nymox 10:30 – 10:55am Pharmaceuticals Tengion Pharmaceutical ZIOPHARM Corp. Kinex Corporation Oncology Pharmaceuticals MJFF (PAG) Fireside Chat with Synthetic DURECT Corporation TBD TBD John Milligan, PhD, 11:00 – 11:25am Biologics Hydra President and COO, Biosciences Gilead Sciences (Astor)
Prosensa Therapeutics 11:30 – 11:55am NanoViricides Prima Biomed Ltd. Astex Protalix KaloBios Pharmaceuticals BioTherapeutics Pharmaceuticals Business Development: Oncology: 12:00 – 12:55pm Putting a Ring on It—When Drug Development Deals The CLL Chronicles— (Box Lunch) Turn into Acquisitions (Astor) The Next Chapter in Clinical Developments (Jade) OncoGenex Sucampo 1:00 – 1:25pm Pharmaceuticals Regulus Therapeutics pSiVida Corp. Pharmaceuticals Alkermes plc
iCo BioDelivery Arena The Road Less 1:30 – 1:55pm Oragenics Immunovaccine Therapeutics Sciences Pharmaceuticals Traveled: International Alternative Avenues DARA SciClone to Public Markets 2:00 – 2:25pm BioLineRx Ltd. Aradigm Corp. BioSciences Pharmaceuticals Orexigen (Jade) Transcept EpiCept Alnylam 2:30 – 2:55pm Pharmaceuticals GeoVax Labs Corporation Cytokinetics Pharmaceuticals Newron 3:00 – 3:25pm Pharmaceuticals Soligenix OncoSec Aastrom Idenix S.p.A Medical Biosciences Pharmaceuticals Fireside Chat with JJ Bienaimé 3:30 – 3:55pm Pozen Retrophin OXiGENE NicOx S.A. PDL BioPharma CEO, BioMarin (Astor) 4:00 – 4:55pm Closing Plenary: Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff (Jade) 5:00 – 6:00pm Closing Happy Hour (Silver Corridor)
-15- Who Should Attend?
Audience Profile
Conference Size 1,150+ One-on-One PartneringTM Meetings 1,300+ Investors Attending 600 Company Presentations 140
Attendees by Title
Analyst Director 11% 15% V.P. 11% Executive Manager 36% 10% Associate 10% Other 7%
Over 1,100 attendees from 16 different countries Over 35% of attendees are executives
-16- Reserve your space today!
3 BIO offers a number of ways for conference attendees to save money on their registration fees.
3 Discounted packages for presenting companies bringing three or more attendees.
3 Special rates for academics and service providers.
Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors. Go to bio.org/bioceo/register and register now.
Group Package: 3+ People Individual Packages: 1-2 people Academic Service Providers Investors Public Company Private Company-New! Public Company Private Company-New! Additional Attendee Registration Fee Registration Fee Registration Fee $5,785 members $4,795 members $1,495 members $1,495 members $1,095 members $895 members $3,195 members Complimentary Early Rate $8,295 non-members $7,095 non-members $2,195 non-members $2,195 non-members $1,695 non-members $895 non-members $4,195 non-members $6,396 members $5,395 members $1,895 members $1,895 members $1,395 members $895 members $4,195 members Complimentary Late Rate $9,295 non-members $8,095 non-members $2,895 non-members $2,895 non-members $2,895 non-members $895 non-members $5,195 non-members Additional rate: Additional rate: $2,895 members $1,895 members Presentation $3,795 non-members $2,595 non-members Presenter Registration Early additional attendee: Early additional attendee: $1,095 members $1,095 members $1,695 non-members $1,695 non-members Late additional attendee: Late additional attendee: 2 additional $1,395 members $1,395 members registrations $2,895 non-members $2,895 non-members
1x1 Partnering Opening Reception Networking Breakfasts Attend Company Presentations Programming Panels
2 people with presentation: Early Member 3 people with presentation: 3 people with presentation: 1 person with presentation: 1 person with presentation: Public- $5,785 Rate Total: $5,785 $4,795 $4,390 $3,390 Private- $3,485
Early Non- 2 people with presentation: Member Rate 3 people with presentation: 3 people with presentation: 1 person with presentation: 1 person with presentation: Public- $7,685 Total: $8,295 $7,095 $5,990 $4,790 Private- $6,485
Book now and save 10%!
Join the conversation: Learn more about Biotechnology at bio.org Engage with the Biotech Community at BIOtech-NOW.org Follow us on Twitter @bio1x1 or #BIOCEO13 Become a fan on Facebook (facebook.com/IAmBiotech)
-17- Sponsors
Supporting Bank Sponsors
BIO Double Helix Sponsors BIO Helix Sponsors
Conference Supporters
Member FINRA/SIPC
Media Partners
Local Co-Host
Contact us today for a tailored sponsorship package to meet your business objectives. Contact Matt Lowe at [email protected] or call 202.312.9277. For more information on BIO sponsorships, please visit www.bio.org/sponsor Barcelona, Spain March 11-13, 2013
The BIO Convention TM Vienna, Austria in China November 4-6, 2013 Beijing, China BIO Investor ForumTM Fall 2013 San Francisco October 8-9, 2013
New York City January 2014 February 10-11, 2014
bio.org/events A Vital Business Catalyst.